SR One related stories
All articles and analysis
In brief: SR One beats target for sophomore biotech fundSR One Capital Management, a transatlantic biotech VC firm that spun out of GlaxoSmithKline, has closed on more than $600 million for its second fund, beating its $500 million target.
VC-backed biopharma company Mineralys Therapeutics raises $192m for IPOThe stock began trading February 10, 2023 on the NASDAQ under the ticker symbol "MLYS."
Ancora Biotech scores $60m in round co-led by Lightspeed and SR OneAncora Biotech will use the funding to boost the clinical development of its trio of antibody treatments.
Nomic Bio inks $17m Series A financing led by Lux CapitalMontreal-based protein profiling company Nomic Bio has secured $17 million in Series A financing.
TCG X expands investment team with new hirePreviously, he worked at Ghost Tree Capital where he was a senior analyst.
- GSK spinout SR One collects $500m for fund
SR One, a biotech venture firm that recently spun out from GlaxoSmithKline, has raised $500 million for its new fund.
- Dren Bio rallies $60m Series A
San Carlos, California-based Dren Bio Inc, a biotech company, has secured $60 million in Series A funding.
- Palleon Pharmaceuticals lands $100m Series B
Palleon Pharmaceuticals, a biotech company, has closed $100 million in Series B financing.
- VC-backed Pandion Therapeutics debuts IPO
Watertown, Massachusetts-based Pandion Therapeutics Inc, a developer of treatments for patients suffering from autoimmune diseases, has raised $135 million for its IPO after pricing its 7.5 million shares at $18 per share.
- Tranquis Therapeutics rakes in $30m Series A
Tranquis Therapeutics, a private immuno-neurology company, has raised $30 million in Series A funding.